89bio
Subsidiary of Roche (RHHBY)
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FGFR1c/2c/3c–β-Klotho agonistProtein / enzyme therapeutic | MASH / NASHSevere Hypertriglyceridemia |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
June 2028 (1)
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Est. primary completion 2028-06-30 · NCT06419374 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Est. primary completion 2029-02 · NCT06318169 · CT.gov ↗
What to watch
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | — | $104M | $129M | $112M | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | — | $64M | $315M | $71M | report ↗ |
| 2024-Q3 | — | $141M | $91M | $149M | report ↗ |
| 2024-Q2 | — | $45M | $212M | $48M | report ↗ |
| 2024-Q1 | — | $47M | $218M | $52M | report ↗ |
| 2023-Q3 | — | $31M | $252M | $35M | report ↗ |
| 2023-Q2 | — | $35M | $245M | $38M | report ↗ |
| 2023-Q1 | — | $22M | $351M | $29M | report ↗ |
| 2022-Q3 | — | $22M | $72M | $27M | report ↗ |
| 2022-Q2 | — | $20M | $61M | $25M | report ↗ |
| 2022-Q1 | — | $20M | $55M | $26M | report ↗ |
| 2021-Q3 | — | $24M | $40M | $28M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $345M | $126M | $92M | report ↗ |
89bio reported R&D spend of $345.04M, up 182.3% YoY, cash and equivalents of $126.06M, and a net loss of $367.08M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text